Financial Performance - The net profit attributable to shareholders for 2017 is expected to increase by CNY 214.45 million to CNY 321.68 million, representing a year-on-year growth of 40% to 60%[2] - The increase in profit is primarily driven by sales growth of the company's products[5] - After excluding non-recurring gains, the net profit attributable to shareholders is expected to rise by CNY 196.13 million to CNY 303.36 million, reflecting a year-on-year growth of 38% to 58%[3] - The net profit for the same period last year was CNY 536.13 million, with a net profit excluding non-recurring gains of CNY 522.40 million[4] - Earnings per share for the previous year was CNY 0.89[4] Non-Recurring Gains - Non-recurring gains are expected to increase by 133.41% year-on-year, mainly due to the disposal of shares in Fujian Tai'er Technology Co., Ltd., impacting current profits by approximately CNY 21.32 million[2] Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[6] - The above forecast data is preliminary and subject to final audited financial results[7]

片仔癀 2017 年第三季度报告 公司代码：600436 公司简称：片仔癀 漳州片仔癀药业股份有限公司 2017 年第三季度报告 福建·漳州 二 0 一七年十月二十七日 1 / 22 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 11 | 片仔癀 2017 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 5,486,720,773.10 5,037,818,928.88 8.91 归属于上市公司股东 的净资产 4,037,025,687.97 3,493,402,147.91 15.56 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的现金 流量净额 708,009,148.67 308,854,425.38 129.24 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （% ...

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 1,752,831,341.08, representing an increase of 82.50% compared to the same period last year[17]. - The net profit attributable to shareholders for the same period was CNY 433,198,861.81, up 41.83% year-on-year[17]. - The net cash flow from operating activities reached CNY 445,169,044.05, a significant increase of 139.76% compared to the previous year[17]. - The basic earnings per share for the first half of 2017 was CNY 0.72, reflecting a growth of 41.18% from CNY 0.51 in the same period last year[18]. - The company achieved operating revenue of RMB 1.75 billion, a year-on-year increase of 82.50%[41]. - Operating profit for the current period was ¥505,157,857.19, up 39.5% from ¥361,851,055.05 in the previous period[126]. - Total profit for the current period was ¥508,504,768.06, compared to ¥363,192,154.40 in the previous period, marking an increase of 40%[126]. - The company reported a net loss of RMB 5,200,508 for the first half of 2017, with total revenue of RMB 4,154,819, resulting in a loss per share of 0.69[101]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 4,995,800,740.04, a slight decrease of 0.83% from the previous year[17]. - Total liabilities decreased from CNY 1,287,069,933.72 to CNY 984,209,386.60, a reduction of approximately 23.6%[120]. - Current liabilities totaled CNY 907,079,412.07, slightly down from CNY 910,035,359.11, indicating a marginal decrease of 0.2%[120]. - Non-current liabilities significantly decreased from CNY 377,034,574.61 to CNY 77,129,974.53, representing a decline of about 79.6%[120]. - The company's cash and cash equivalents decreased to RMB 1.630 billion from RMB 1.706 billion at the end of the previous year[119]. - The company's inventory increased to RMB 1.188 billion, up from RMB 1.126 billion at the end of the previous year[119]. Investment and Research - Research and development expenses amounted to RMB 21.41 million, a slight decrease of 3.34% year-on-year[41]. - The company has established a "cooperation + no-walled research institute" R&D model to enhance its research capabilities[38]. - The company reported investment income of ¥28,680,142.94, up from ¥6,834,307.02 in the previous period, indicating a strong growth in investment returns[126]. Sales and Marketing - The domestic sales model includes regional distribution, VIP sales, and direct sales through company-owned stores, enhancing market reach and customer engagement[28]. - The VIP sales model targets high-end customers, offering personalized services to increase brand loyalty and sales of the company's products[28]. - The company has established "experience halls" in collaboration with pharmaceutical distribution companies to enhance brand recognition and product sales through interactive experiences[29]. Compliance and Quality Control - The company holds valid drug production and operation licenses, ensuring compliance with regulatory standards[23]. - The company strictly follows production quality management standards, with quality inspection departments monitoring key production stages to ensure product quality[24]. Procurement and Supply Chain - The company's procurement strategy includes a focus on quality and price, with a structured procurement process involving bidding and supplier selection based on market conditions[26]. - The company's main raw materials include musk, ox gall, snake bile, and others, with significant procurement amounts for musk and snake bile, which require specific governmental licenses for procurement[25]. Corporate Governance and Shareholder Information - The company has a total of 59,859 common stock shareholders as of the end of the reporting period[99]. - The largest shareholder, Zhangzhou Jiulongjiang Group Co., Ltd., holds 349,455,750 shares, accounting for 57.92% of the total shares[100]. - The company has not experienced any environmental protection incidents or received administrative penalties during the reporting period[95]. Financial Obligations and Guarantees - The company reported a total guarantee amount of 6,000.00 million RMB for external guarantees, with no overdue guarantees[84]. - The total guarantee amount, including guarantees to subsidiaries, is 2,738.54 million RMB, which represents 0.68% of the company's net assets[84]. - The company has no guarantees provided to shareholders, actual controllers, or their related parties[84]. Strategic Initiatives - The company is actively expanding its product line to include health foods, functional beverages, and cosmetics, in addition to its core pharmaceutical products[23]. - The company has implemented a brand strategy focused on quality and innovation to drive growth[36]. - The company is investing in artificial musk farming to mitigate risks related to the supply and price of raw materials[68]. Legal Matters - The company is involved in a significant lawsuit seeking RMB 98 million in damages for trademark infringement and unfair competition against Xiamen Traditional Chinese Medicine Factory and others[73]. Accounting and Financial Reporting - The company has not made any changes to its accounting policies or estimates during the reporting period[96]. - The company’s financial statements are prepared based on the continuous operation principle, in accordance with relevant accounting standards[146]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[154].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 本公告所载2017年半年度主要财务数据为初步核算数据，未经会计师事务所 审计，具体数据以公司2017年半年度报告中披露的数据为准，提请投资者注意投 资风险。 一、2017年半年度主要财务数据和指标 单位：万元 证券代码：600436 证券简称：片仔癀 公告编号：2017-047 漳州片仔癀药业股份有限公司 2017年半年度业绩快报公告 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 （％） | | --- | --- | --- | --- | | 营业总收入 | 175,353.10 | 96,043.31 | 82.58 | | 营业利润 | 50,352.91 | 36,185.11 | 39.15 | | 利润总额 | 50,687.56 | 36,319.22 | 39.56 | | 归属于上市公司股 东的净利润 | 43,335.53 | 30,543.57 | 41.88 | | 基本每股收益（元） | 0.72 | 0.51 | 41.18 | | ...

Financial Performance - The company's operating revenue for 2016 was CNY 2,308,954,269.71, representing a year-on-year increase of 22.45% compared to CNY 1,885,674,673.52 in 2015[18]. - The net profit attributable to shareholders of the listed company for 2016 was CNY 536,131,906.97, an increase of 14.88% from CNY 466,676,722.67 in 2015[18]. - The cash dividend distribution plan for 2016 is CNY 2.7 per 10 shares, totaling CNY 162,895,646.70, which accounts for 30.38% of the net profit attributable to shareholders[2]. - The basic earnings per share for 2016 was CNY 0.89, reflecting a 15.58% increase from CNY 0.77 in 2015[19]. - The weighted average return on equity for 2016 was 16.20%, an increase of 0.77 percentage points from 15.43% in 2015[19]. - The net cash flow from operating activities for 2016 was CNY 394,537,198.88, up 29.14% from CNY 305,510,311.56 in 2015[18]. - The company's total assets as of December 31, 2016, were CNY 5,037,818,928.88, a 24.24% increase from CNY 4,054,922,388.84 in 2015[18]. - The company's net assets attributable to shareholders at the end of 2016 were CNY 3,493,402,147.91, a 10.71% increase from CNY 3,155,385,463.37 in 2015[18]. Revenue and Profit Analysis - The company's total revenue for the year reached 230,895.43 million RMB, with a significant increase in the fourth quarter revenue to 68,327.61 million RMB, representing a growth compared to previous quarters[22]. - The net profit attributable to shareholders for the fourth quarter was 55,075.18 million RMB, showing a decline from earlier quarters due to increased operating costs and expenses[22]. - The gross profit margin for the year was 48.95%, with a notable drop in the fourth quarter to 35.30% as a result of higher costs associated with the newly acquired pharmaceutical distribution business[23]. - Sales expenses increased significantly in the fourth quarter, totaling 10,257.94 million RMB, driven by sales contract adjustments and increased marketing efforts, including the opening of 36 new experience centers[25]. - The company reported a net cash flow from operating activities of 85,682.77 million RMB in the fourth quarter, indicating strong cash generation despite the profit decline[22]. Market and Product Development - The company has expanded its product line to include health and wellness products, enhancing its market presence beyond traditional pharmaceuticals[33]. - The pharmaceutical industry is experiencing rapid growth, driven by increasing healthcare demands and supportive government policies[39]. - The traditional Chinese medicine sector is a significant part of the pharmaceutical industry, with a strong market presence due to its low side effects and wide availability[40]. - The international market is increasingly recognizing the value of natural medicines, creating a favorable environment for the development of traditional Chinese medicine[40]. - The company aims to expand its business in pharmaceutical circulation, daily chemicals, and health food sectors as part of its "one core and two wings" health development strategy[64]. Research and Development - R&D expenditure increased by 32.70% to CNY 66,945,255.78, reflecting a commitment to innovation and product development[60]. - The company is actively engaged in research and development, collaborating with various research institutions to enhance its product offerings and technological capabilities[49]. - The company has a total of 8 patents for its main product, Pien Tze Huang, with patent protection extending until 2032[2]. - The company is currently conducting clinical trials for a new pain relief drug, with an investment of 671.00 million RMB, and is in the preclinical research phase[101]. - The company plans to expand its product line and enhance its competitiveness in the pharmaceutical industry through ongoing R&D efforts[102]. Operational Costs and Expenses - The company's management expenses for the year totaled 21,758.61 million RMB, with a management expense ratio of 9.42%[23]. - The total main business cost for the company increased by 18.36% to ¥1,176,155.15 million, primarily due to increased sales revenue[69]. - The total operating cost for the year was 2,031.04 million, an increase of 8.81% compared to the previous year[71]. - Sales expenses increased by 65.13% to 274.83 million, primarily due to increased promotional and advertising expenditures[74]. Strategic Initiatives - The company implemented a "one core, two wings" strategy to drive growth in the health industry, focusing on both internal and external resource integration[53]. - The company plans to strengthen sales channels and expand its market presence, focusing on both domestic and overseas markets[141]. - The company intends to integrate high-quality industry resources through mergers and acquisitions to enhance product sales scale[142]. - The company has established partnerships with local governments to facilitate growth, resulting in a 32.15% increase in operational efficiency[168]. Social Responsibility and Community Engagement - The company has actively engaged in poverty alleviation efforts, including building bridges, water projects, and cultural parks in impoverished villages[180]. - The company has a commitment to timely repayment of loans, with specific repayment dates outlined for each loan[176]. - The company has been recognized for its social responsibility initiatives, receiving praise from various sectors of society[180]. Risks and Compliance - The company faces risks from potential drug price reductions due to ongoing healthcare reforms and high raw material costs[143]. - The company has implemented strict GMP regulations to ensure product quality and environmental protection, which are critical for its operations[144]. - The company has maintained a strong focus on regulatory compliance and is closely monitoring drug procurement policies to adapt its sales strategies accordingly[111].

公司代码：600436 公司简称：片仔癀 漳州片仔癀药业股份有限公司 2017 年第一季度报告 2007 年 4 月 13 日 1 / 22 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 10 | 一、 重要提示 二、 公司基本情况 4 / 22 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | -142,400.35 | | | 计入当期损益的政府补助，但与公 | 3,316,895.83 | | 3 / 22 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 5,046,204,213.98 5,037,818,928.88 0.17 归属于上市公司 股东的净资产 3,721,148,961.26 3,493,402,147.91 6.52 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) ...

Financial Performance - The company expects a net profit attributable to shareholders for Q1 2017 to increase by approximately 50% to 60% compared to the same period last year [3]. - The net profit for the same period last year was 146.6423 million yuan [4]. - The earnings per share for the same period last year was 0.24 yuan [4]. - The increase in profit is primarily driven by the growth in sales of the company's leading product, Pian Zai Huang, and its series of products [5]. - The company has improved its profitability through effective cost control measures [5]. Cautionary Notes - The financial data provided is preliminary and subject to final confirmation in the official Q1 2017 report [6]. - Investors are advised to be cautious regarding investment risks based on the preliminary data [6].

证券代码：600436 证券简称：片仔癀 公告编号：2017-001 漳州片仔癀药业股份有限公司 2016年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 本公告所载2016年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2016年年度报告中披露的数据为准，提请投资者注意投资风 险。 算。 2 、归属于上市公司股东的每股净资产期初数以资本公积金转增股本后的 数据进行了重新计算。 3、本报告的其他期初数同法定披露的上年年末数。 二、经营业绩和财务状况情况说明 1、股本增长50%主要系本公司2016年度实施资本公积金转增股本所致。 一、2016年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 229,283.34 | 188,567.47 | 21.59 | | 营业利润 | 61,252.44 | 54,159.43 | 13.10 | | ...

2016 年第三季度报告 公司代码：600436 公司简称：片仔癀 漳州片仔癀药业股份有限公司 2016 年第三季度报告 1 / 25 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 4 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 12 | 2016 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人刘建顺、主管会计工作负责人庄建珍及会计机构负责人（会计主管人员）杨志红 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 3 / 25 2016 年第三季度报告 二、 公司主要财务数据和股东变化 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | | 本期金额 | 年初至报告期末金 | | 说明 | | -- ...

Financial Performance - The company achieved total operating revenue of CNY 960,433,098.24, an increase of 18.01% compared to the same period last year[15]. - The net profit attributable to shareholders of the listed company was CNY 305,435,740.45, representing a growth of 21.07% year-on-year[15]. - The net cash flow from operating activities reached CNY 185,676,068.80, up 58.38% from the previous year[15]. - Basic earnings per share increased to CNY 0.51, a rise of 21.43% compared to the same period last year[16]. - The company's total revenue reached 944.78 million RMB, reflecting a year-on-year increase of 16.57%[42]. - Operating profit for the current period was ¥361,851,055.05, reflecting a growth of 22.0% from ¥296,415,657.23 in the last period[140]. - Net profit for the current period was ¥309,047,016.07, representing a 22.4% increase compared to ¥252,384,192.87 in the previous period[140]. - The company reported a net decrease in cash and cash equivalents of ¥105,578,896.08, compared to a decrease of ¥65,255,181.21 in the prior period[147]. Assets and Liabilities - The company's total assets amounted to CNY 4,253,225,674.56, reflecting a growth of 4.89% from the end of the previous year[15]. - The company's total liabilities amounted to CNY 841,957,777.95, up from CNY 751,596,928.38, indicating an increase of approximately 12.0%[132]. - Current liabilities rose to CNY 468,742,000.63, compared to CNY 361,881,496.38, marking an increase of about 29.5%[132]. - The total non-current assets increased to CNY 1,403,300,735.71 from CNY 1,231,204,773.49, reflecting a growth of approximately 13.9%[132]. Investments and Expenditures - Research and development expenditure increased by 12.41% to 22.15 million RMB, indicating a continued commitment to technological innovation[29]. - The company established a joint venture with Shanghai Jahwa to expand into the oral care industry, enhancing its product portfolio[23]. - The company reported a significant increase in long-term equity investments, with a total of 437.25 million RMB, up 110.15% year-on-year[36]. - The company invested a total of 277.01 million RMB during the reporting period, a significant increase of 835.13% compared to 29.62 million RMB in the same period last year[46]. Market and Sales Strategy - The company focused on marketing innovation and brand influence enhancement through the promotion of the "Pian Zai Huang" experience center model[21]. - The company expanded its sales channels by promoting "Pian Zai Huang" capsules in hospitals and leveraging the O2O health management platform[21]. - Domestic revenue was 803.37 million RMB, up 14.32% year-on-year, while overseas revenue reached 141.41 million RMB, a 31.20% increase[44]. - The company is focusing on e-commerce growth by increasing investments and support for new product launches and brand promotion[23]. Operational Efficiency and Management - The company actively engaged in management innovation to enhance operational efficiency and risk control[22]. - The weighted average return on net assets increased to 9.38%, up by 1.07 percentage points year-on-year[16]. - The company has established a comprehensive internal control system to mitigate operational risks and ensure compliance with laws and regulations[93]. - The board of directors and management team have effectively fulfilled their responsibilities, ensuring the company's interests are prioritized[92]. Shareholder and Capital Structure - The company distributed cash dividends of 140.77 million RMB, accounting for 30% of the net profit attributable to shareholders in the consolidated financial statements[66]. - The company’s capital stock increased to 603.32 million RMB, a rise of 49.93% from 402.21 million RMB, due to the conversion of capital reserves into share capital[39]. - The total number of shareholders reached 55,575 by the end of the reporting period[102]. - The largest shareholder, Zhangzhou Jiulongjiang Group Co., Ltd., holds 349,455,750 shares, representing 57.92% of the total shares[105]. Legal and Compliance Matters - The company is involved in a lawsuit seeking RMB 98 million in damages for trademark infringement and unfair competition, with an additional RMB 600,000 for legal fees[71]. - The lawsuit has not yet gone to trial, and the impact on the company's current or future profits cannot be accurately assessed at this time[71]. - There are no ongoing bankruptcy reorganization matters applicable to the company[72]. Future Outlook and Guidance - The company provided guidance for Q3 2023, expecting revenue to be between $1.6 billion and $1.8 billion, representing a growth rate of 10% to 20%[3]. - The company is expanding its market presence in Asia, targeting a 25% increase in market share by the end of 2024[5]. - New product launches included a cutting-edge software platform that is projected to generate an additional $200 million in revenue over the next year[4].